Low LeverageThe company’s minimal reported debt materially lowers near-term refinancing and interest-rate risk, preserving financial flexibility. For a loss-making biotech/generic player, low leverage provides runway options (equity, partnerships, or selective financing) and reduces default probability while management pursues operational fixes.
Occasional Free Cash Flow ImprovementAn identifiable improvement in free cash flow in 2024 versus 2023 shows management can implement cost or working-capital measures that materially reduce cash burn. That operational responsiveness is a durable capability: if repeated, it supports progressing to self-funded operations or extending the time to required financing.
Positive EPS Growth MetricReported EPS growth (≈62%) indicates an improving earnings per share trajectory over the measured period, suggesting some operational or structural improvements. If sustained, rising EPS helps restore investor confidence, eases capital raising, and signals progress toward profitability beyond transient cost cuts.